Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Brams
Doug Brams, Seattle, WA US
| Patent application number | Description | Published |
|---|---|---|
| 20100277416 | DIRECTIONAL INPUT SYSTEM WITH AUTOMATIC CORRECTION - A system associated with a text entry application, such as email or instant messaging, comprises an optional onscreen representation of a circular keyboard, a list of potential linguistic object matches, and a message area where the selected words are entered. The circular keyboard is manipulated via a hardware joystick or game-pad with analog joystick or omni-directional rocker switch built therein. The user points the joystick in the general direction of the desired letter, and then continues pointing roughly to each letter in the desired word. Once all letters have been roughly selected, buttons are used to select a specific word from the list of potential matches and send the selected word to the message area. | 11-04-2010 |
Peter Brams, Campbell, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090010939 | IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS - The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection. | 01-08-2009 |
| 20090012271 | IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS - The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection. | 01-08-2009 |
| 20090124791 | IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS - The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection. | 05-14-2009 |
Peter Brams, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080282363 | METHODS FOR PRODUCING HUMAN ANTIBODIES IN SCID MICE - An improved method for producing human antibodies in SCID mice is provided. The improvement includes the use of dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents. | 11-13-2008 |
Scott F. Brams, Elkins Park, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20120078440 | METHODS AND SYSTEMS FOR INTEGRATION OF VEHICLE SYSTEMS - In one aspect, an information terminal of a vehicle has a display device and a vehicle interface connecting to a plurality of distinct vehicle communications platforms supporting a plurality of vehicle systems. It also has a storage device storing an operating system of the vehicle information terminal, a plurality of graphical operator interface (GUI) applications corresponding to the vehicle systems and configured to execute on the operating system, and one or more processors. The one or more processors are configured to execute the GUI application on the operating system to display a GUI window on the display device, the GUI window providing for an operator's selection at least some of the plurality of GUI applications, to receive a selection by the operator of a GUI application, and to interface with the vehicle system to which the selected GUI application corresponds over the vehicle communications platform via the GUI window. | 03-29-2012 |
Steven J. Brams, New York City, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20090076944 | System for valuing and transferring interests in property or other goods - The invention that is the subject of this Disclosure is a method for valuing and transferring interests in property (whether real or personal, tangible or intangible) or goods. The system involves having parties that hold ownership interests in property or goods disclose to a third-party (but not to each other) a price at which they would be willing to either sell their interests to the other side, or buy out the other side's interests, submitting binding offers to the third party obliging them either to buy or sell at their stated price (in the unlikely event that the stated prices are the same), or, alternatively, at some other price in between the ones set forth in their offers that is more favorable to each of them and that is identified by the third party. The third party then makes a binding determination as to who shall buy, and who shall sell, and makes a binding determination as to the sale price, by following certain protocols and applying a formula, agreed to by the parties in advance, with respect to the numerical values submitted by the respective parties. The invention allows each party to always arrive at an agreed upon outcome, and allows each party always to arrive at an outcome that is either equal to or more favorable to that party than the outcome that that party proposed. | 03-19-2009 |